Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâ€™s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

10-23 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
31/08/26	SEK 1.270	+2.42%	45,455
28/08/26	SEK 1.240	-1.20%	86,340
27/08/26	SEK 1.255	-0.40%	11,045
26/08/26	SEK 1.260	0.00%	132,000
25/08/26	SEK 1.260	+4.56%	164,623

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 15:42:39 31/08/2026 +04			5-day change	1st Jan Change
1.270 ^SEK	+2.42%		+5.39%	+11.40%

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI

Market Cap	119M 12.44M 10.72M 10.05M 9.18M 17.29M 1.19B 17.34M 46.53M 600M 46.71M 45.69M 1.99B	P/E 2026 *	-13.8x	P/E 2027 *	-3.26x
Enterprise Value	82.25M 8.58M 7.39M 6.93M 6.33M 11.92M 820M 11.96M 32.09M 414M 32.22M 31.52M 1.37B	EV / Sales 2026 *	2.84x	EV / Sales 2027 *	-
Free-Float	41.18%	Yield 2026 *	-	Yield 2027 *	-

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT
04-24	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Iconovo Q1 net sales up at 0.7 mln SEK	RE
04-14	Iconovo appoints Anders Mañsson as CEO	RE
04-14	Iconovo AB Appoints Anders Månsson as Permanent CEO, Effective April 14, 2026	CI
03-17	Iconovo says no TO 1 was used for subscription	RE
03-02	Iconovo announces final outcome of rights issue	RE
02-25	Iconovo and Lonza sign LOI regarding strategic collaboration	RE
02-24	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
02-12	Iconovo Q4 net sales SEK 504,000	RE
02-12	Iconovo AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

08-24	Iconovo: Still waiting for commercial proof – Q2 review	AQ
07-03	Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB	AQ
06-29	Iconovo terminates liquidity provider agreement	AQ
06-22	Iconovo and Lonza sign Strategic Collaboration Agreement	AQ
04-24	Iconovo: Limited progress – Q1 review	AQ

Iconovo AB Stock

Stocks

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Valuation : Iconovo AB

Chart: Iconovo AB

Latest news : Iconovo AB

Analysts' recommendations : Iconovo AB

Press Releases : Iconovo AB

Quotes and Performance

Price Extremes

Managers and Directors : Iconovo AB

Latest insider transactions

Medical Supplies

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	+2.42%
1 week	+5.39%
Current month	+23.30%
1 month	+23.30%
3 months	+7.63%
6 months	+12.39%
Current year	+11.40%

1 week	1.2	1.28
1 month	0.9	1.28
Current year	0.87	1.44
1 year	0.87	2.51
3 years	0.87	17.4
5 years	0.87	90
10 years	0.87	99.8

Manager	Title	Age	Since
Anders Månsson CEO	Chief Executive Officer	59	31/10/2025
Henrik Simonsen DFI	Director of Finance/CFO	63	01/04/2023
Mikael Arinder COO	Chief Operating Officer	62	01/01/2016

Director	Title	Age	Since
Mats Håkan Johansson CHM	Chairman	65	01/01/2013
Orest Lastow BRD	Director/Board Member	62	01/01/2013
Berndt David Lennart Axelsson BRD	Director/Board Member	67	01/01/2013

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/09/22	Mats Håkan Johansson	Buy	Founder	500	0.0057%
21/09/22	Johan Wäborg	Buy	Chief Executive Officer	1,000	0.0113%
16/09/22	Agneta Walhagen	Buy	Director	840	0.0095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICONOVO AB	+2.42%	+5.39%	-48.58%	-92.23%	12.44M
COLOPLAST A/S	-0.43%	-0.69%	-26.37%	-41.51%	16.17B
INTCO MEDICAL TECHNOLOGY CO., LTD.	-3.19%	+12.17%	+47.84%	+158.57%	5.23B
ZHENDE MEDICAL CO., LTD.	+0.02%	+2.80%	+246.13%	+218.12%	3.3B
WINNER MEDICAL CO., LTD.	-0.03%	+3.00%	-29.44%	-28.71%	2.55B
JAFRON BIOMEDICAL CO.,LTD.	0.00%	+0.89%	-30.90%	-25.56%	1.83B
TOP GLOVE CORPORATION BHD.	-3.65%	-0.75%	+12.82%	-13.73%	1.31B
GVS S.P.A.	+0.63%	+1.06%	+2.81%	-17.22%	1.03B
ZHONGHONG PULIN MEDICAL PRODUCTS CO., LTD.	-5.16%	+8.62%	+11.11%	+19.65%	1.02B
ANHUI HONGYU WUZHOU MEDICAL MANUFACTURER CO.,LTD.	-6.21%	+3.22%	+123.40%	+168.23%	1B
Average	-1.56%	+3.34%	+30.88%	+34.56%	3.35B
Weighted average by Cap.	-1.16%	+5.39%	+19.65%	+27.15%

	2026 *	2027 *
Net sales	29M 3.03M 2.61M 2.44M 2.23M 4.2M 289M 4.22M 11.31M 146M 11.36M 11.11M 484M	-
Net income	-6M -626K -539K -506K -462K -870K -59.82M -872K -2.34M -30.2M -2.35M -2.3M -100M	-37M -3.86M -3.33M -3.12M -2.85M -5.36M -369M -5.38M -14.44M -186M -14.49M -14.18M -617M
Net Debt	-37M -3.86M -3.33M -3.12M -2.85M -5.36M -369M -5.38M -14.44M -186M -14.49M -14.18M -617M	-44M -4.59M -3.96M -3.71M -3.39M -6.38M -439M -6.4M -17.17M -221M -17.23M -16.86M -734M